Visar inlägg med etikett EMPE. Visa alla inlägg
Visar inlägg med etikett EMPE. Visa alla inlägg

onsdag 26 februari 2020

Join the initiative Vision Zero for Healthcare-Associated Infections in India!


Actors from academia and the public and private sectors met in Stockholm on a sunny afternoon last week to talk about healthcare-associated infections in India and how to combat them. The background is an initiative taken by Swedish companies Essity, EMPE Diagnostics and Bactiguard, to take a lead position towards combatting healthcare-associated infections in India. The first steps to "Vision Zero on Healthcare-Associated Infections" were taken during the delegation trip to India in February 2019, headed by Minister for Health Lena Hallengren.

Healthcare-Associated Infections (HAIs) are an important public health problem globally. HAIs occur worldwide and affect all countries, irrespective of their degree of development. +50% of all HAI are caused by bacterial growth on medical devices, such as catheters. They represent a significant burden among patients, health-care workers and health systems - but are in many cases preventable. In India, it is estimated that more than 2 million people are affected each year.



Cecilia Edström, recently appointed CEO of Bactiguard, introduced the seminar by saying that she is a a strong believer in the triple helix approach, where academia and public and private sectors can work towards the same goal. This initiative is an attempt to build collaborative ecosystems in healthcare across India, to capture the learning’s of Sweden and contribute towards leading the path of substantially reduced HAI in India -  to reduce infections, reduce complications for patients, free up bed capacity and lower the cost of treatment.


The pre-study that has been done was presented by Aticka Chona, consultant at Green Karmas. The study’s purpose was to clearly understand the expectations of the Indian authorities and healthcare industry, and to develop a structure and engagement plan to take forward the co-operation. The pre-study has also raised awareness and interest among various public and private care providers, such as AIIMS, Max, Medanta, Apollo and the Healthcare Sector Skills Council. The interest from the Indian side in the vision has been keen interest, which has been beneficial for the founding companies.
All of the actors said that they know which their challenges are, and what can be done – but they need to learn HOW to do that and how others have done it. The answer lies in Education, education, education. Swedish healthcare is well-known and our work on infection control can be a role model. They know learn more about pre-diagnosis, to build a digital solution based on what has been done in Sweden but then adapted to Indian conditions and they would like continuous contact – handholding – on how to address infections in the hospitals.

The continuation of the project is planned in two phases. The first one will focus on ICU challenges, and the second will be focused on general hospitals challenges. The work will be done through a series of joint working groups between Swedish companies, Indian hospitals and healthcare organizations on the topic of HAI.



The present group of Swedish companies and the Indian hospitals are now ready to take the next step, to bring global best practices, data and knowledge from Sweden to Indian healthcare actors. By joining the Vision Zero for HAI in India, partners can work towards the same goal and actually make a difference. This can then serve as a basis for business opportunities for the Swedish companies – getting access to a chain of hospital through only one entry point is a great advantage!

The initiative is now looking for more Swedish stakeholders that want to share their expertise and solutions, and to capitalize on the work already done for Vision Zero for HAI in India. For more information, please contact aticka.chona[@[greenkarmas.com or anna.riby[a]Swecare.se.



fredag 29 september 2017

Central Baltic Health Access trip to India - Sept 2017

Key takeaways


1. You have to be excited to be there. If being in India does not make you happy then it will be very hard to motivate yourself and your team to invest time and money necessary to succeed in the Indian market. Two of the participants woke up at 2am to visit the Taj Mahal from Delhi (+3hrs one-way by car) before their 11am meetings with agencies and distributors. This passion speaks for itself, and the Indian counterparts are much more likely to go an extra mile (in this case quite literally) if you show that you are doing so yourself.

2. A physical presence is extremely important. Most people will actually want to meet you first and then take it from there. If, in the Swedish manner, you try to book meeting weeks in advance with a set agenda, the response is unlikely to be overwhelming. One of our Swedish delegates was so concerned with what she saw as a lack of planning that she "almost didn't come, [...] but there were so many good meetings that were unprepared!" She booked her ticket days before this CBHA trip and was not disappointed.

3. When your extremely talented and dedicated local coach tells you to take an Indian SIM card, listen to him. I regretted not having taken an old phone with me as many of my texts did not go through and data connectivity was patchy at best. There was no WiFi at the conference venue which made it difficult to follow-up and set-up meetings with the leads one had just met, an Indian number would have made life much easier.

4. Use Whatsapp - one of the representatives of a government regulatory body said that he is unlikely to ever answer an email as he is constantly running between meetings and stuck in traffic (many official domains are inaccessible on the mobile). Get potential partners' mobile numbers and use them.


About the trip


The third installment of the Central Baltic Health Access project consisted of three days in Delhi and two days in Bengaluru over the third week in September. The sheer variety of meetings we managed to fit into these few days is nothing short of impressive. For this we have Sachin Gaur and his team at InnovatioCuris to thank. I believe I speak for all participants - six from Sweden, five from Estonia, and four from Finland - when I say that it was a productive trip. Company mission reviews have started to come in and we will book in coaching meetings over the next few weeks in order to ensure follow-up, but the general feeling, even after two days in Delhi, was that many promising connections have been made - with distributors, clinics, hospitals, start-ups, research institutes, regulatory agencies.
We were also privileged to have hands-on support from both the Estonian and Swedish Embassies in Delhi. The Ambassadors spent a considerable amount of time with the companies, in order to understand the needs, challenges, and expectations of each representative. This type of local support is key for success in foreign markets. In fact Swecare is already in talks with the Embassy, Business Sweden, InnovatioCuris, Confederation of Indian Industry (CII), and Federation of Indian Chambers of Commerce & Industry (FICCI) to explore the option of making this type of business-focused trips a regular event. If you are interested in this form of deep engagement, do let us know!


Participants:


Representative name
Organization
Dr. Jaanus Pikani
Documental, Estonia
Ms. Piia Vettik-Leemet
Tartu Biotechnology Park, Estonia
Mr. Jan Erik Hedborg
ApiRays, Sweden
Mr. Priit Aigro
Smart Do, Estonia
Ms. Maarika Merirand
Tehnopol, Estonia
Dr. Pieter Spee
Fibrotx, Estonia
Ms. Malin Hollmark
Swedish Medtech, Sweden
Ms. Shampa Bari
Swecare, Sweden
Mr. Hakan Jideus
Predicare, Sweden
Mr. Pavan Asalapuram
Empe diagnostics, Sweden
Ms. Caroline Danielson
RenaPharma, Sweden
Mr. Joonas Ihalainen
iCare, Finland
Mr. Tero Karhi
Turku Science Park, Finland
Dr. Katja Heikkinen
Turku AMK, Finland
Ms. Marjatta Häsänen
Turku AMK, Finland


Food for thought


Before signing off, I leave you with some few points I have pondering over since the trip.

- If the diagnostic test costs more than the 'cure,' often antibiotics, wouldn't you too just take the latter?
- How to tackle the aging challenge, which the Indian healthcare system is only now coming to see as a threat?
- Can our products be price-competitive when there is such heavy tax imposed on imports into India? Is manufacturing there a viable option?
- When it comes to product tests, must the companies fund the research themselves, or are there easily available funds in Sweden? The Indian research agencies have such funds for the work being done on their end but cannot finance the Swedish engagement, making the PPP project less tenable.